titlesubmit dateissue date
Now showing items 1-3 of 3
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
Gαq activation modulates autophagy by promoting mTORC1 signaling.
Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers